In a report issued on November 22, Mani Foroohar from Leerink Partners reiterated a Hold rating on Alnylam Pharma (ALNY – Research Report). The company’s shares closed last Tuesday at $183.80.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.6% and a 30.6% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and Adverum Biotechnologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $211.12 average price target, which is a 16.3% upside from current levels. In a report issued on November 22, BMO Capital also maintained a Hold rating on the stock with a $180.00 price target.
See the top stocks recommended by analysts >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $188 million and GAAP net loss of $205 million. In comparison, last year the company earned revenue of $126 million and had a GAAP net loss of $253 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More on ALNY: